HRAS mutation prevalence and associated expression patterns in pheochromocytoma.

Regarding clinical parameters, no mutations were found in PPGLs classified as malignant according to the current WHO criteria and the patients endowed with a HRAS mutation tended to have higher age at diagnosis (mean 63 ±10 years) compared with those without HRAS mutation (mean 54 ±16 years) however this association did not reach statistical significance (two‐tailed Mann–Whitney U ‐test, P = 0.08).

also in 111,027 other papers